Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics

The development of acquired resistance to anti-EGFR therapies remains poorly understood, with most research to date exploring, and trying to overcome, various genomic mechanisms of resistance. However, recent work supports a model of resistance whereby transcriptomic mechanisms of resistance predomi...

Full description

Bibliographic Details
Main Authors:	Christine Parseghian, Madhulika Eluri, Scott Kopetz, Kanwal Raghav
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-09-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	anti-EGFR anti-EGFR rechallenge genomic mechanisms of resistance to anti-EGFR non-genomic mechanisms of resistance to anti-EGFR anti-EGFR resistance
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2023.1176657/full

Similar Items

Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
by: Kim JS, et al.
Published: (2018-08-01)

Targeting long non-coding RNAs as new modulators in anti-EGFR resistance mechanisms
by: Mostafa Akbarzadeh-Khiavi, et al.
Published: (2024-01-01)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022-01-01)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-02-01)

Lycopene minimizes skin toxicity and oxidative stress in patients treated with panitumumab-containing therapy for metastatic colorectal cancer
by: Mauro Moroni, et al.
Published: (2021-08-01)

Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
by: Deepak Vangala, et al.
Published: (2021-07-01)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
by: Adithya Chennamadhavuni, et al.
Published: (2022-06-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015-09-01)

Research Progress of the Resistance Mechanism of Non-small Cell Lung Cancer  to EGFR-TKIs
by: Huihui LIU, et al.
Published: (2013-10-01)

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
by: Kyu Sic You, et al.
Published: (2021-06-01)

Anti-Inflammatory Effect of Resveratrol Derivatives via the Downregulation of Oxidative-Stress-Dependent and c-Src Transactivation EGFR Pathways on Rat Mesangial Cells
by: I-Ta Lee, et al.
Published: (2022-04-01)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
by: Li Liu, et al.
Published: (2021-10-01)

A high expression EGFR/cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening EGFR antagonists from Rhizoma Polygoni Cuspidati
by: Meng Sun, et al.
Published: (2011-08-01)

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
by: Shubin Chen, et al.
Published: (2023-06-01)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)

Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case report
by: Alfonso De Stefano, et al.
Published: (2023-02-01)

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
by: Yongkang Bai, et al.
Published: (2023-04-01)

pSTAT3 transactivates EGFR in maintaining EGFR protein homeostasis and EGFR-TKI resistance
by: Ao Juan, et al.
Published: (2024-09-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
by: Kamal Eltayeb, et al.
Published: (2022-01-01)

EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones
by: Arafa Musa, et al.
Published: (2022-02-01)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
by: Kaiwen Wang, PharmD, et al.
Published: (2023-08-01)

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
by: Tia Cheunkarndee, BA, et al.
Published: (2024-06-01)

Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling
by: Najah Albadari, et al.
Published: (2024-01-01)

REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
by: Hiromichi Nakajima, et al.
Published: (2021-06-01)

An Improvement of Exertional Dyspnea by the Reintroduction of Anti-EGFR Antibody in Patients with Metastatic Rectal Cancer Who Developed Cancerous Lymphangiopathy: A Case Report
by: Masatsune Shibutani, et al.
Published: (2024-03-01)

Design, Synthesis, and Anti-Proliferative Action of Purine/Pteridine-Based Derivatives as Dual Inhibitors of EGFR and BRAF<sup>V600E</sup>
by: Samar A. El-Kalyoubi, et al.
Published: (2023-05-01)

Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer
by: Tamotsu Sagawa, et al.
Published: (2023-06-01)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
by: Yurong Wang, et al.
Published: (2021-11-01)

Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
by: Alejandro Ríos-Hoyo, et al.
Published: (2024-04-01)

Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies
by: Hiroshi Nakatsumi, et al.
Published: (2022-11-01)

ANALYSIS OF IMMUNOHISTOCHEMICAL EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) IN COLORECTAL CANCER
by: Ghazala Sadaf, et al.
Published: (2020-10-01)

Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first‐line EGFR inhibitor resistance in lung cancer
by: Yen‐Ting Lin, et al.
Published: (2024-01-01)

Resistance to Both Chemotherapy and EGFR-TKI in Small Cell Lung Cancer With EGFR 19-Del Mutation: A Case Report
by: Lingfei Wang, et al.
Published: (2020-07-01)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
by: Peijun Cao, et al.
Published: (2022-03-01)

Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications
by: Nina Shaban, et al.
Published: (2023-12-01)

The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance
by: Albina Kibirova, et al.
Published: (2019-10-01)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
by: Natthaporn Sueangoen, et al.
Published: (2020-03-01)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
by: Chunfa Qian, et al.
Published: (2022-11-01)

Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation
by: Yajie Cheng, et al.
Published: (2022-08-01)